January 31, 2025 expert reaction to NICE final draft guidance on exagamglogene autotemcel (exa-cel) for severe sickle cell disease . Scientists comment on final draft guidance fro ...

Intensive chemo is used before treatment with gene-editing medicines, including Vertex's CRISPR Therapeutics-partnered Casgevy (exagamglogene autotemcel), which became the first based on the ...

The £1.65m treatment, known as exagamglogene autotemcel (exa-cel), is a one-time gene therapy ... a Nigerian-born obstetrician-gynecologist based in Canada, had taken legal action against the ...

Data suggest that a single use of exagamglogene autotemcel (exa-cel, brand name Casgevy ... who reported having experienced poor care in the past year, 56% had taken no action. But 30% gave feedback ...

The question of putative mechanisms of action continues to haunt psychopharmacology. Put simply, we know these drugs work, but we have very little idea how. We make guesses based on the ...

The SARS-CoV-2 pandemic interrupted much respiratory research. Respiratory clinical academics joined colleagues in providing clinical care, and global research efforts were directed to finding new ...

Inc.'s ("Editas") payment rights under a non-exclusive license to Vertex Pharmaceuticals Incorporated ("Vertex") of Editas Medicine's Cas9 gene-editing technology for CASGEVY® (exagamglogene ...

CASGEVY ® (exagamglogene autotemcel). The reimbursement agreement comes as the National Institute for Health and Care Excellence (NICE) issues positive guidance recommending CASGEVY’s use in ...